United States Anxiety Disorders and Depression Treatment Market Report by Product, Indication, States and Company Analysis, 2026-2034

United States Anxiety Disorders and Depression Treatment Market Size and Forecast 2026-2034

United States Anxiety Disorders and Depression Treatment Market is expected to reach US$ 32.53 Billion by 2034 from US$ 20.93 Billion in 2025, with a CAGR of 5.02% from 2026 to 2034. Growing mental-health awareness, rising diagnosis rates, expanding insurance coverage, increasing use of telepsychiatry, treatment innovation, digital therapeutics, and demand for faster-acting medicines are supporting the United States anxiety and depression treatment industry.

United States Anxiety Disorders and Depression Treatment Industry Overview

The United States anxiety disorders and depression treatment industry represents a broad healthcare ecosystem encompassing prescription medicines, psychotherapy, behavioral-health services, digital mental-health platforms, telepsychiatry, hospital-based care, outpatient treatment, and emerging neuromodulation approaches. Anxiety disorders remain highly prevalent among U.S. adults, with NIMH estimating that 19.1% of adults experience any anxiety disorder in a given year. Generalized anxiety disorder alone affects an estimated 2.7% of U.S. adults annually. These conditions generate substantial demand for diagnosis, pharmacological intervention, counseling, psychotherapy, and ongoing disease management.

Depression is similarly creating sustained demand across the U.S. behavioral-health system. CDC data indicate that depression prevalence among adolescents and adults increased substantially over the past decade, while nearly 40% of people aged 12 and older with depression received counseling or therapy from a health professional during the preceding year. More than one in ten U.S. adults also reported prescription medication use for depression in 2023. These trends demonstrate the continuing importance of both pharmaceutical and non-pharmaceutical treatment channels.

The treatment landscape is evolving beyond conventional selective serotonin reuptake inhibitors and other established antidepressants. New mechanisms, combination therapies, rapid-acting approaches, digital interventions, personalized treatment strategies, and novel psychiatric drug-development programs are broadening therapeutic possibilities. The FDA has also taken recent steps to accelerate development of treatments for serious mental illnesses, including depression and treatment-resistant conditions. In April 2026, the agency announced regulatory initiatives supporting research into serotonin-2A agonists and related psychedelic medicines.

Recent Developments in United States Anxiety Disorders and Depression Treatment Market

• In January 2025, Johnson & Johnson announced that SPRAVATO(R) (esketamine) had received FDA clearance, making it the first monotherapy for those with treatment-resistant depression in the US. When compared to a placebo, the medication demonstrated rapid efficacy.
• In December 2024, the FDA approved Eli Lilly's Zepbound (tirzepatide) for people with moderate to severe obstructive sleep apnea who were obese, marking a significant advancement in U.S. treatment options.

Key Forces Driving Market Expansion

Increasing Recognition and Diagnosis of Mental-Health Conditions

Growing recognition of anxiety and depression is one of the strongest structural drivers for the U.S. treatment market. Public awareness campaigns, primary-care screening, workplace mental-health programs, school-based initiatives, and improved understanding of psychiatric symptoms are encouraging more individuals to seek professional assistance. Anxiety disorders affect a substantial proportion of the U.S. adult population, creating a large potential treatment pool. NIMH estimates that 19.1% of U.S. adults experience any anxiety disorder during a year, while generalized anxiety disorder affects approximately 2.7%. Increased awareness can also reduce the stigma historically associated with psychiatric treatment, encouraging individuals to pursue medication, psychotherapy, or combined approaches.

The expansion of screening within primary-care settings is another important factor. Physicians increasingly recognize that untreated anxiety and depression can affect productivity, relationships, physical health, treatment adherence, and overall quality of life. Earlier diagnosis can increase the probability that patients enter treatment pathways before symptoms become more severe. Consequently, greater awareness, improved screening, and changing attitudes toward mental-health care are expected to continue supporting demand for therapeutic services and medications.

Expansion of Telepsychiatry and Digital Behavioral Healthcare

The development of telepsychiatry and digital behavioral-health services has significantly changed access to anxiety and depression treatment in the United States. Virtual consultations allow patients to communicate with psychiatrists, psychologists, therapists, and other behavioral-health professionals without requiring frequent physical visits. This model can be particularly useful for individuals living in areas with limited access to mental-health specialists.

Digital platforms are also supporting appointment scheduling, symptom tracking, behavioral interventions, medication-management programs, and remote follow-up. Employers, insurers, healthcare systems, and specialized technology providers are increasingly integrating digital behavioral-health solutions into broader care models. These services can complement conventional pharmaceutical treatment and psychotherapy rather than replacing them completely.

Improved connectivity and consumer familiarity with virtual healthcare are supporting continued adoption. Digital treatment models may also help address transportation barriers, scheduling difficulties, and provider shortages. As reimbursement structures and clinical evidence evolve, technology-enabled behavioral healthcare is likely to remain an important component of the U.S. anxiety and depression treatment ecosystem.

Development of Faster-Acting and Mechanistically Differentiated Treatments

Another major growth driver is pharmaceutical innovation aimed at patients who do not respond adequately to conventional therapies. Traditional antidepressants can require several weeks before patients experience meaningful improvement, creating opportunities for therapies designed to produce faster or more differentiated effects.

Pharmaceutical and biotechnology companies are exploring novel neurotransmitter pathways, glutamatergic mechanisms, neuroactive steroids, psychedelic-related approaches, combination medicines, and other emerging technologies. The FDA's recent initiatives concerning serious mental illness and serotonin-2A agonist research demonstrate growing regulatory attention toward innovative treatment approaches.

The need is particularly significant among individuals with treatment-resistant depression or persistent anxiety symptoms. New therapies that demonstrate improved efficacy, tolerability, onset of action, or convenience could capture significant demand. Innovation may also encourage personalized treatment approaches in which patients are matched with therapies based on clinical history, symptom patterns, biological characteristics, and previous treatment response.

Major Challenges Affecting the Industry

Treatment Access, Cost and Behavioral-Health Workforce Constraints

Despite increasing demand, access to anxiety and depression treatment remains uneven across the United States. Patients may encounter difficulties related to insurance coverage, high out-of-pocket expenses, limited provider availability, geographic disparities, long appointment waiting periods, and inadequate continuity of care.

The behavioral-health workforce also faces capacity constraints in several regions. Shortages of psychiatrists, psychologists, therapists, and specialized professionals can delay diagnosis and treatment. Patients may therefore rely heavily on primary-care providers, emergency departments, community clinics, or digital platforms.

Medication affordability can create another barrier, particularly for newer branded treatments that may have higher costs than generic antidepressants. Insurance authorization requirements and formulary restrictions can further influence prescribing decisions. Addressing these challenges will require improved reimbursement, workforce expansion, integrated care models, telehealth infrastructure, and broader availability of evidence-based behavioral-health services.

Treatment Response Variability and Side-Effect Concerns

Anxiety and depression are heterogeneous conditions, and patients can respond differently to the same treatment. A medicine that provides substantial improvement for one patient may offer limited benefit to another. Conventional antidepressants may also be associated with adverse effects that influence adherence and long-term treatment continuation.

Treatment switching, dose adjustments, combination therapy, and psychotherapy can increase healthcare utilization and treatment complexity. For patients with treatment-resistant depression, finding an effective intervention may require multiple therapeutic strategies.

The industry therefore faces pressure to develop treatments with better efficacy, tolerability, faster onset, and more predictable outcomes. Clinical trials must also demonstrate meaningful benefits while adequately evaluating safety. As novel therapies enter the market, healthcare providers and payers will need to balance clinical value against acquisition and administration costs.

California Anxiety Disorders and Depression Treatment Market

California represents one of the largest potential markets for anxiety and depression treatment in the United States due to its substantial population, extensive healthcare infrastructure, large concentration of medical institutions, and growing behavioral-health awareness. The state has a diverse patient population and significant demand for outpatient psychiatric services, psychotherapy, prescription medications, telepsychiatry, and digital behavioral-health platforms. Large metropolitan areas such as Los Angeles, San Francisco, San Diego, and Sacramento support extensive networks of hospitals, clinics, academic medical centers, and private behavioral-health providers. California's technology ecosystem also encourages development and adoption of digital mental-health tools, remote monitoring platforms, and healthcare applications. Employers and health systems increasingly recognize the economic impact of untreated mental-health conditions, supporting investment in employee assistance programs and integrated behavioral-health models. The market is expected to benefit from continuing innovation, although affordability, insurance coverage, provider availability, and geographic disparities remain important considerations.

Texas Anxiety Disorders and Depression Treatment Market

Texas offers substantial opportunities for anxiety and depression treatment providers because of its large and rapidly growing population, extensive healthcare network, and significant urban centers. Houston, Dallas-Fort Worth, Austin, and San Antonio contain large concentrations of hospitals, specialty clinics, behavioral-health providers, and pharmaceutical distribution infrastructure. Demand is supported by increased awareness of mental health and the growing integration of behavioral healthcare into primary-care settings. Telepsychiatry is particularly relevant for serving geographically dispersed populations and communities where specialist availability may be limited. Pharmaceutical treatment remains important, while psychotherapy, counseling, digital behavioral-health services, and community-based programs contribute to a diversified treatment ecosystem. Healthcare organizations are increasingly focusing on earlier identification and coordinated care for anxiety and depressive disorders. However, differences in insurance coverage, provider availability, affordability, and access between metropolitan and rural communities may influence treatment utilization and market development across the state.

New York Anxiety Disorders and Depression Treatment Market

New York represents an important market for anxiety and depression treatment due to its dense population, advanced healthcare infrastructure, strong academic research ecosystem, and concentration of specialized psychiatric providers. New York City contains numerous hospitals, academic medical centers, private practices, community clinics, and behavioral-health organizations, supporting a broad range of treatment options. The state also provides a favorable environment for clinical research into psychiatric medicines and innovative behavioral-health approaches. Demand encompasses antidepressant medications, psychotherapy, psychiatric consultations, telehealth, intensive outpatient programs, and digital interventions. Increasing awareness of mental-health needs among younger adults and working populations is contributing to greater utilization of professional services. Integrated care models are also becoming more relevant as providers seek to address depression and anxiety alongside physical health conditions. Nevertheless, provider shortages, treatment affordability, insurance restrictions, and differences in access between metropolitan and rural communities remain challenges for market participants.

Florida Anxiety Disorders and Depression Treatment Market

Florida's anxiety and depression treatment market is supported by its large and diverse population, extensive healthcare sector, and substantial demand for services among older adults, working-age residents, and younger populations. Major metropolitan regions including Miami, Orlando, Tampa, Jacksonville, and Fort Lauderdale provide significant concentrations of hospitals, outpatient clinics, psychiatrists, psychologists, and behavioral-health organizations. The state's growing healthcare infrastructure supports pharmaceutical treatment, psychotherapy, counseling, telepsychiatry, and community-based programs. Digital mental-health services are also relevant because they can improve access for patients who face transportation or geographic barriers. Providers increasingly emphasize coordinated care and early identification of depressive and anxiety symptoms. Florida's large retiree population also creates demand for integrated behavioral healthcare in older adults, particularly where depression may occur alongside chronic disease or social isolation. Market expansion may nevertheless be influenced by insurance coverage, affordability, specialist availability, and differences in access across communities.

Antidepressant Drugs Market

Antidepressant drugs remain a foundational component of the U.S. depression-treatment ecosystem and are also widely used for selected anxiety disorders. Established drug classes include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, tricyclic antidepressants, and monoamine oxidase inhibitors. Generic availability supports broad accessibility, while newer branded medicines compete through differentiated mechanisms, dosing profiles, speed of action, or specific clinical positioning.

The segment continues to evolve as pharmaceutical companies investigate treatments capable of addressing inadequate response to conventional antidepressants. In 2025, FDA records included generic buspirone approval for anxiety-disorder management, illustrating continued competition from generic therapies.

Meanwhile, differentiated products such as Auvelity demonstrate the industry's interest in alternative mechanisms for major depressive disorder. Pharmaceutical companies are increasingly pursuing lifecycle extensions, novel combinations, and treatments for specific patient populations. The antidepressant segment is therefore characterized by a combination of high-volume generic medicines and premium innovative therapies. Future growth will depend on prescription volumes, treatment adherence, new-product launches, reimbursement, clinical differentiation, and the ability of emerging therapies to demonstrate meaningful benefits over established options.

Major Depressive Disorder Market

Major depressive disorder represents a major component of the U.S. mental-health treatment landscape, generating demand for antidepressant medications, psychotherapy, psychiatric consultations, digital interventions, neuromodulation, and hospital-based services. The condition can range from mild to severe and may require different treatment strategies depending on symptom intensity, previous treatment response, comorbidities, and patient preferences.

The market is increasingly focused on treatment-resistant and difficult-to-treat depression, where conventional approaches may provide insufficient benefit. This is creating opportunities for therapies with novel mechanisms and potentially faster onset. Regulatory interest in innovative treatments for serious mental illness is also strengthening the development environment.

The segment is simultaneously supported by growing awareness, screening, improved diagnosis, and broader acceptance of mental-health treatment. Counselling and psychotherapy remain important alongside medicines, while digital platforms and telepsychiatry are expanding access. Future market development will depend on innovation, affordability, insurance coverage, treatment adherence, clinical outcomes, and the ability of healthcare providers to deliver personalized, continuous care.

Research Methodology of United States Anxiety Disorders and Depression Treatment Market

The United States Anxiety Disorders and Depression Treatment Market was estimated using a combination of bottom-up and top-down approaches, supported by extensive secondary research and data triangulation. The methodology was designed to assess the size of the addressable patient population, diagnosis and treatment rates, medication utilization, psychotherapy adoption, treatment costs, prescription volumes, and healthcare expenditure. Publicly available information from government agencies, healthcare organizations, medical publications, pharmaceutical databases, company disclosures, and other reliable sources was analyzed to develop historical market estimates and forecast future growth. The estimates were further cross-verified against independent healthcare and pharmaceutical indicators to improve consistency and reliability.

1. Market Definition and Scope

• The United States Anxiety Disorders and Depression Treatment Market was first defined to establish a clear and consistent framework for the estimation.
• The analysis covered treatments, therapies, and healthcare interventions used for the management of anxiety disorders and depressive disorders among patients in the United States.
• The market was further segmented by:
• Product
• Indication
• States
• Segmentation was determined based on the availability of reliable secondary information.

2. Extensive Secondary Research

• The estimation was primarily based on extensive secondary research rather than primary interviews or surveys.
• Information was collected from authoritative government institutions, healthcare organizations, medical publications, pharmaceutical databases, company disclosures, and other reliable industry sources.
• The major sources reviewed included:
• U.S. government health agencies and healthcare databases
• National Institute of Mental Health (NIMH) publications
• Centers for Disease Control and Prevention (CDC) data
• Substance Abuse and Mental Health Services Administration (SAMHSA) reports
• U.S. Food and Drug Administration (FDA) databases
• National Institutes of Health (NIH) publications
• Peer-reviewed psychiatric and medical journals
• Professional psychiatric and psychological associations
• Prescription and pharmaceutical databases
• Clinical-trial and drug-development databases
• Company annual reports and investor presentations
• Pharmaceutical company product disclosures
• Healthcare expenditure and reimbursement publications
• Insurance and healthcare utilization information
• Academic research papers and systematic reviews
• The collected information was used to establish:
• Addressable patient population
• Treatment penetration
• Medication utilization
• Therapy adoption
• Treatment expenditure
• Historical market trends

3. Assessment of Anxiety and Depression Patient Population

• The potential patient population was assessed separately for anxiety disorders and depressive disorders.
• Published prevalence estimates and national health statistics were reviewed to determine the number of people affected by these conditions in the United States.
• The analysis differentiated between:
• Total population affected by the conditions
• Diagnosed patients
• Patients seeking professional treatment
• Patients receiving medication
• Patients receiving psychotherapy or counseling
• This distinction was important because the number of people experiencing anxiety or depression did not necessarily represent the number of patients contributing directly to treatment-market revenue.
• Published prevalence rates were applied to relevant U.S. population groups where appropriate.
• Demographic differences, including age group and sex, were considered when sufficiently reliable information was available.

4. Estimation of Diagnosed and Treatment-Seeking Population

• After estimating the affected population, the diagnosed and treatment-seeking population was assessed.
• Not every individual experiencing anxiety or depression was assumed to have received a formal diagnosis or treatment.
• Treatment rates were examined using publicly available healthcare utilization statistics and mental-health treatment studies.
• The analysis considered the proportion of affected individuals who:
• Accessed healthcare professionals
• Received a diagnosis
• Obtained prescriptions
• Attended therapy sessions
• Used other recognized treatment services
• The calculation was structured as:
• Affected Population X Diagnosis Rate X Treatment Rate = Addressable Treated Population
• Separate assumptions were developed for anxiety disorders and depressive disorders when differences in diagnosis or treatment utilization were identified.

5. Disease-Type Segmentation

• The market was divided into major disease categories to avoid combining conditions with substantially different treatment patterns.
• The anxiety disorders segment included conditions such as:
• Obsessive-Compulsive Disorder
• Major Depressive Disorder
• Phobia
• Others
• The patient population, treatment utilization, and expenditure were assessed separately for each disease category.
• This enabled the market estimate to reflect differences in:
• Prevalence
• Medication selection
• Treatment duration
• Therapy utilization

6. Prescription Volume and Utilization Analysis

• Prescription utilization was analyzed to estimate pharmaceutical market revenue.
• Available prescription data were reviewed to identify the number of prescriptions issued for major anxiety and depression treatments.
• The analysis considered:
• Prescription volume
• Number of treated patients
• Prescription frequency
• Average treatment duration
• Refills
• Generic versus branded prescriptions
• New versus continuing prescriptions
• Drug-class utilization
• Changes in prescribing patterns
• Where prescription data were available, they were used as an important validation point for the pharmaceutical portion of the market.

7. Average Treatment Cost Assessment

• Average treatment expenditure was estimated using publicly available information on medication prices, healthcare expenditure, reimbursement, and therapy costs.
• For pharmaceutical treatments, the analysis considered:
• Average prescription prices
• Annual treatment costs
• Generic substitution
• Branded products
• For psychotherapy and counseling, treatment expenditure was assessed using information on:
• Average session costs
• Treatment frequency
• Typical treatment duration
• The calculation was broadly structured as:
• Treated Patients X Average Annual Treatment Cost = Estimated Treatment Revenue
• Separate calculations were performed for different treatment categories to improve accuracy.

8. Bottom-Up Market Estimation

• A detailed bottom-up methodology was applied to estimate the market size.
• The U.S. population was first divided according to anxiety and depression conditions.
• The diagnosed and treated population was then calculated using treatment penetration assumptions derived from secondary sources.
• For each treatment category, the estimated number of treated patients was multiplied by the applicable annual treatment expenditure.
• For pharmaceutical treatment:
• Number of Treated Patients X Annual Medication Expenditure = Pharmaceutical Market Value
• For therapy:
• Number of Treated Patients X Average Number of Sessions X Average Cost per Session = Therapy Market Value
• The revenue generated from the major treatment categories was then aggregated.
• The overall calculation was:
• Total Market Value = Pharmaceutical Treatment Revenue + Therapy Market Revenue + Other Included Treatment Revenue

9. Top-Down Market Validation

• The bottom-up estimate was subsequently validated through a top-down approach.
• Broader U.S. healthcare expenditure, mental-health spending, pharmaceutical sales, prescription data, healthcare utilization statistics, and published expenditure estimates were reviewed to establish an independent reference point.
• The estimated market value was compared with relevant healthcare spending categories to determine whether the calculated market size was reasonable.
• Where a significant difference existed between the bottom-up and top-down estimates, the underlying assumptions were reviewed.
• Adjustments were made to:
• Treatment penetration
• Average expenditure
• Prescription utilization
• Segment allocation
• Adjustments were made only where the available secondary evidence supported such changes.

10. Pharmaceutical Revenue Cross-Checking

• The pharmaceutical component was cross-checked using publicly available information relating to major products and drug classes.
• Company annual reports, financial filings, product disclosures, prescription information, regulatory documents, and pharmaceutical databases were reviewed to understand sales trends and product performance.
• The analysis also considered:
• Generic drug availability
• Patent expirations
• New product approvals
• Changes in prescribing behavior
• Drug discontinuations
• New indications
• Treatment guideline changes

11. Psychotherapy and Behavioral Treatment Estimation

• The psychotherapy segment was estimated separately because its revenue structure differed from pharmaceutical treatment.
• The analysis considered:
• Number of patients receiving psychotherapy or counseling
• Frequency of treatment sessions
• Average treatment duration
• Estimated expenditure per session
• Different treatment patterns were considered for patients receiving short-term and long-term therapy.
• Where secondary sources provided information on insurance coverage or reimbursement, these factors were incorporated into the assessment.
• The therapy estimate was then combined with pharmaceutical treatment revenue after ensuring that overlapping patient groups were appropriately accounted for.

12. Patient Group Analysis

• The market was evaluated across major patient groups where reliable information was available.
• The analysis considered:
• Adults
• Adolescents
• Older adults
• Other clinically relevant patient groups
• Differences in the following factors were examined:
• Disease prevalence
• Diagnosis
• Treatment-seeking behavior
• Medication utilization
• Therapy adoption
• This segmentation helped account for variations in treatment intensity and healthcare utilization across different population groups.

13. Historical Market Analysis

• Historical market trends were established by analyzing changes in:
• Disease prevalence
• Diagnosis rates
• Treatment adoption
• Prescription utilization
• Healthcare expenditure
• Access to mental-health services
• The historical analysis also considered changes in the treatment landscape, including:
• Introduction of new medications
• Increasing use of generic drugs
• Evolving treatment guidelines
• Growing adoption of psychotherapy
• Greater availability of digital and remote mental-health services
• Historical estimates were developed using a consistent methodology across the assessment period to ensure comparability between years.

14. Emerging Treatment Assessment

• Emerging treatment approaches were reviewed to determine their potential contribution to the market.
• The analysis considered:
• Digital mental-health platforms
• Telepsychiatry
• Technology-assisted therapy
• Novel pharmacological treatments
• Other emerging treatment approaches where commercially relevant and supported by secondary information
• New regulatory approvals, clinical developments, product launches, and changes in treatment guidelines were reviewed to understand their potential impact on future treatment adoption.

15. Forecast Market Estimation

• The future market was forecast by analyzing the expected development of the patient population and treatment economics.
• Forecast assumptions included:
• Anxiety and depression prevalence
• Diagnosis rates
• Treatment-seeking behavior
• Treatment penetration
• Prescription volumes
• Medication prices
• Generic substitution
• Adoption of innovative therapies
• Psychotherapy utilization
• Healthcare accessibility
• Insurance coverage
• Regulatory developments
• Changes in treatment guidelines
• Each major treatment segment was forecast separately before being aggregated into the overall United States market.
• The forecast was therefore not based on applying a single growth rate to the historical market.
• Instead, the underlying market drivers were evaluated individually to develop a more realistic projection.

16. Data Triangulation

• The final market estimate was developed through data triangulation.
• Information obtained from patient prevalence studies was compared with:
• Treatment utilization data
• Prescription statistics
• Healthcare expenditure information
• Pharmaceutical sales
• Company disclosures
• Where multiple sources provided different estimates, the differences were investigated based on:
• Publication year
• Geographic coverage
• Patient definition
• Disease definition
• Treatment definition
• Methodology
• Reliability
• Relevance to the U.S. market
• The most relevant and reliable information was prioritized, while inconsistent or outdated estimates were adjusted or excluded.

17. Final Market Size Calculation

• After completing the bottom-up calculation, top-down validation, treatment segmentation, pricing analysis, and data triangulation, the final United States Anxiety Disorders and Depression Treatment Market size was calculated.
• The final calculation was represented as:
• United States Anxiety Disorders and Depression Treatment Market = Anxiety Treatment Market + Depression Treatment Market
• Where:
• Anxiety Treatment Market = Pharmaceutical Treatment + Psychotherapy/Other Treatment
• Depression Treatment Market = Pharmaceutical Treatment + Psychotherapy/Other Treatment
• The estimates for each segment were reconciled to ensure that patients receiving multiple treatments were not counted more than once when calculating the overall patient population.

18. Final Cross-Verification

• Finally, the calculated market size was cross-verified against:
• Available industry estimates
• Government healthcare expenditure information
• Pharmaceutical sales trends
• Prescription data
• Published medical literature
• The final estimate was accepted only after the major assumptions had been reviewed for consistency and the calculated values had been reconciled with available secondary evidence.
• This methodology resulted in a structured and evidence-based estimation of the United States Anxiety Disorders and Depression Treatment Market, with the market value derived from:
• Patient population
• Treatment penetration
• Treatment utilization
• Pricing
• Pharmaceutical sales
• Therapy expenditure
• Broader healthcare trends
• The estimation did not rely on a single published market figure.

Market Segmentations

Product

• Antidepressant Drugs
• Therapy and Devices
• Others

Indication

• Obsessive-Compulsive Disorder
• Major Depressive Disorder
• Phobia
• Others

States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Abbvie
• Bristol-Myers Squibb Company
• Eli Lily & Co
• GlaxoSmithKline
• H. Lundbeck A/S
• Johnson & Johnson
• Merck & Co. Inc
• Pfizer Inc
• Sanofi-Aventis
• Axsome Therapeutics